Jamjoom Pharma net profit up 94% to SAR 84.4 mln in Q1

Jamjoom Pharma net profit up 94% to SAR 84.4 mln in Q1

02/07/2023 Argaam Exclusive

View other reports

Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) posted a net profit of SAR 84.4 million in Q1 2023, a 94% increase from SAR 43.5 million a year earlier.



Current Quarter Comparison (M)

Compared With The
Item Q1 2022 Q1 2023 Change‬
Revenues 243.78 300.85 23.4 %
Gross Income 164.32 199.61 21.5 %
Operating Income 77.42 93.91 21.3 %
Net Income 43.53 84.40 93.9 %
Average Shares 70.00 70.00 -
EPS (Riyals) 0.62 1.21 93.9 %

The positive performance was driven by 23.9% increase in revenue driven by strong demand for the company's products, price increases approved by SFDA for some of key products during the latter part of Q1 2023 and better-than-expected growth of the pharma market.

 

Sequentially, net profit jumped 165% from SAR 31.80 million in Q4 2022 as revenue rose 53.5%.

Shareholders’ equity, no minority interest, stood at SAR 1.26 billion as of March 31, 2023, compared to SAR 1.23 billion a year earlier.

 

View More Financial Results

 


Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
Q1 2014 - - - - - -
Q2 2014 - - - - - -
Q3 2014 - - - - - -
Q4 2014 - - - - - -
Q1 2015 - - - - - -
Q2 2015 - - - - - -
Q3 2015 - - - - - -
Q4 2015 - - - - - -
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 121.82 - 77.37 - 14.74 -
Q2 2021 193.05 - 124.75 - 49.73 -
Q3 2021 - - - - - -
Q4 2021 - - - - - -
Q1 2022 243.78 100.1 % 164.32 112.4 % 77.42 425.2 %
Q2 2022 238.30 23.4 % 153.06 22.7 % 57.61 15.9 %
Q3 2022 237.76 - 151.13 - 60.03 -
Q4 2022 196.84 - 125.41 - 38.26 -
Q1 2023 300.85 23.4 % 199.61 21.5 % 93.91 21.3 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS Before XO Items
Q1 2014 - - - - - -
Q2 2014 - - - - - -
Q3 2014 - - - - - -
Q4 2014 - - - - - -
Q1 2015 - - - - - -
Q2 2015 - - - - - -
Q3 2015 - - - - - -
Q4 2015 - - - - - -
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 10.98 - 0.16 - 10.98 0.16
Q2 2021 41.19 - 0.59 - 41.19 0.59
Q3 2021 - - - - - -
Q4 2021 - - - - - -
Q1 2022 43.53 296.3 % 0.62 (28.75) 72.28 1.03
Q2 2022 50.42 22.4 % 0.72 (4.27) 54.69 0.78
Q3 2022 45.60 - 0.65 (7.96) 53.56 0.77
Q4 2022 31.76 - 0.45 (6.98) 38.73 0.55
Q1 2023 84.40 93.9 % 1.21 - 84.40 1.21

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 64.79 % 28.15 % 23.92 %
Q1 2023 64.62 % 28.21 % 23.76 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2014 - - - -
Q2 2014 - - - -
Q3 2014 - - - -
Q4 2014 - - - -
Q1 2015 - - - -
Q2 2015 - - - -
Q3 2015 - - - -
Q4 2015 - - - -
Q1 2016 - - - -
Q2 2016 - - - -
Q3 2016 - - - -
Q4 2016 - - - -
Q1 2017 - - - -
Q2 2017 - - - -
Q3 2017 - - - -
Q4 2017 - - - -
Q1 2018 - - - -
Q2 2018 - - - -
Q3 2018 - - - -
Q4 2018 - - - -
Q1 2019 - - - -
Q2 2019 - - - -
Q3 2019 - - - -
Q4 2019 - - - -
Q1 2020 - - - -
Q2 2020 - - - -
Q3 2020 - - - -
Q4 2020 - - - -
Q1 2021 70.00 - - -
Q2 2021 70.00 - - 16.98
Q3 2021 - - - -
Q4 2021 - - - -
Q1 2022 70.00 - - 17.67
Q2 2022 70.00 - - 18.03
Q3 2022 70.00 - - 18.34
Q4 2022 70.00 2.45 3.13 17.38
Q1 2023 70.00 3.03 3.31 18.13

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 - - -
Q1 2023 - - -

Business Segments (Million)

Compared With The
Period Pharmaceutical products Consumer Health Products
Q1 2021 107.12 14.70
Q2 2021 174.82 18.23
Q1 2022 203.09 40.70
Q2 2022 207.60 30.70
Q3 2022 206.65 31.11
Q4 2022 180.05 16.79
Q1 2023 258.50 42.35

Current
Market Cap (M Riyal) 10,990.00
Enterprise Value (EV) (M) 10,868.18
Shares Outstanding ((M)) 70.00
EPS ( Riyal) (TTM) 4.99
Book Value (BV) ( Riyal) 20.64
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 31.45
P/E (TTM) 31.45
Price/book 7.61
Return on Average Assets (%) (TTM) 19.9
Return on Average Equity (%) (TTM) 24.9

Share Price

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.